Imran Rangraze

Dr. Imran Rangraze


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2025 in Cancers
Verified
Journal Article
Open access
PDF file
Mohamed El-TananiMohamed El-Tanani
Mohamed El-Tanani
SRSyed Arman Rabbani
Syed Arman Rabbani
Shakta Mani SatyamShakta Mani Satyam
Shakta Mani Satyam
IRImran Rangraze
Imran Rangraze
AWAdil Farooq Wali
Adil Farooq Wali
Alaa A. A. AljabaliAlaa A. A. Aljabali
Alaa A. A. Aljabali
Cancer stem cells (CSCs) play a central role in tumor progression, recurrence, and resistance to conventional therapies, making them a critical focus in oncology research. This review provides a comprehensive analysis of CSC biology, emphasizing their self-renewal, differentiation, and dynamic interactions with the tumor microenvironment (TME). Key signaling pathways, including Wnt, Notch, and Hedgehog, are discussed in detail to highlight their potential as therapeutic targets. Current methodologies for isolating CSCs are critically examined, addressing their advantages and limitations in advancing precision medicine. Emerging technologies, such as CRISPR/Cas9 and single-cell sequencing, are explored for their transformative potential in unraveling CSC heterogeneity and informing therapeutic strategies. The review also underscores the pivotal role of the TME in supporting CSC survival, promoting metastasis, and contributing to therapeutic resistance. Challenges arising from CSC-driven tumor heterogeneity and dormancy are analyzed, along with strategies to mitigate these barriers, including novel therapeutics and targeted approaches. Ethical considerations and the integration of artificial intelligence in designing CSC-specific therapies are discussed as essential elements of future research. The manuscript advocates for a multi-disciplinary approach that combines innovative technologies, advanced therapeutics, and collaborative research to address the complexities of CSCs. By bridging existing gaps in knowledge and fostering advancements in personalized medicine, this review aims to guide the development of more effective cancer treatment strategies, ultimately improving patient outcomes.

16 September 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
PKPaschalis Karakasis
Paschalis Karakasis
Nikolaos FragakisNikolaos Fragakis
Nikolaos Fragakis
DPDimitrios Patoulias
Dimitrios Patoulias
PTPanagiotis Theofilis
Panagiotis Theofilis
Marios SagrisMarios Sagris
Marios Sagris
MANFREDI RIZZOMANFREDI RIZZO
MANFREDI RIZZO
Obesity is a significant predisposing factor for heart failure with preserved ejection fraction (HFpEF). Although a substantial proportion of individuals with HFpEF also have obesity, those with obesity are under-represented in clinical trials for heart failure. In turn, current guidelines provided limited recommendations for the medical management of this patient population. Both obesity and diabetes induce a pro-inflammatory state that can contribute to endothelial dysfunction and coronary microvascular impairment, finally resulting in HFpEF. Additionally, obesity leads to increased epicardial and chest wall adiposity, which enhances ventricular interdependence. This condition is further aggravated by plasma and blood volume expansion and excessive vasoconstriction, ultimately worsening HFpEF. Despite the well-documented benefits of GLP-1 receptor agonists in subjects with diabetes, obesity, or both, their role in obesity-related HFpEF remains unclear. In light of the recently published literature, this review aims to investigate the potential mechanisms and synthesize the available clinical evidence regarding the role of GLP-1 receptor agonists in patients with obesity-related HFpEF.

Verified
Journal Article
Open access
PDF file
AWAdil Farooq Wali
Adil Farooq Wali
JPJayachithra Ramakrishna Pillai
Jayachithra Ramakrishna Pillai
STSIRAJUNISA TALATH
SIRAJUNISA TALATH
PSPooja Shivappa
Pooja Shivappa
SSSathvik Belagodu Sridhar
Sathvik Belagodu Sridhar
NANowar Nizar Alani
Nowar Nizar Alani
Extensive investigation has been conducted on plant-based resources for their pharmacological usefulness, including various cancer types. The scope of this review is wider than several studies with a particular focus on breast cancer, which is an international health concern while studying sources of flavonoids, carotenoids, polyphenols, saponins, phenolic compounds, terpenoids, and glycosides apart from focusing on nursing. Important findings from prior studies are synthesized to explore these compounds’ sources, mechanisms of action, complementary and synergistic effects, and associated side effects. It was reviewed that the exposure to certain doses of catechins, piperlongumine, lycopene, isoflavones and cucurbitacinfor a sufficient period can provide profound anticancer benefits through biological events such as cell cycle arrest, cells undergoing apoptosis and disruption of signaling pathways including, but not limited to JAK-STAT3, HER2-integrin, and MAPK. Besides, the study also covers the potential adverse effects of these phytochemicals. Regarding mechanisms, the widest attention is paid to Complementary and synergistic strategies are discussed which indicate that it would be realistic to alter the dosage and delivery systems of liposomes, nanoparticles, nanoemulsions, and films to enhance efficacy. Future research directions include refining these delivery approaches, further elucidating molecular mechanisms, and conducting clinical trials to validate findings. These efforts could significantly advance the role of phytocompounds in breast cancer management.

10 February 2025 in Medicina
Verified
Journal Article
Open access
PDF file
SRSyed Arman Rabbani
Syed Arman Rabbani
MPMohamed Anas Patni
Mohamed Anas Patni
Mohamed El-TananiMohamed El-Tanani
Mohamed El-Tanani
IRImran Rangraze
Imran Rangraze
AWAdil Farooq Wali
Adil Farooq Wali
AAAbdelrahman A.Almetwally
Abdelrahman A.Almetwally
Background and Objectives: Cancer survival poses significant challenges in oncology, with lifestyle modifications increasingly recognized as crucial in modifying patient outcomes post-diagnosis. This meta-analysis aims to systematically evaluate the impact of various lifestyle interventions on cancer survival across different types of cancer. Methods: A comprehensive literature search of electronic databases including PubMed, Scopus and Cochrane was performed to identify relevant studies up to 30 November 2024. Relevant studies were chosen and data were extracted and analyzed using SPSS Version 29.0 software. Results: Our systematic review included data from 98 studies involving a total of 1,461,834 cancer patients to evaluate the impact of lifestyle factors on cancer survival. Out of these, 64 studies were included in the meta-analysis. Our meta-analysis demonstrates that adherence to specific dietary patterns significantly improves cancer-specific outcomes. The Healthy Eating Index (HEI) diet was associated with a reduction in cancer-specific mortality (pooled log HR: −0.22; 95% CI: [−0.32, −0.12]; p < 0.001). Similar benefits were observed with the Mediterranean diet (aMED), which also reduced cancer mortality and recurrence (pooled log HR: −0.24; 95% CI: [−0.40, −0.07]; p < 0.001), and the Dietary Approaches to Stop Hypertension (DASH) diet (pooled log HR: −0.22; 95% CI: [−0.33, −0.12]; p < 0.001). Additionally, general dietary improvements were beneficial for breast cancer-specific mortality across 17 cohort studies (pooled log HR: −0.15; 95% CI: [−0.25, −0.06]; p < 0.001). Engaging in any form of physical activity post-diagnosis was associated with significant improvements in cancer-specific mortality or recurrence (pooled log HR: −0.31; 95% CI: [−0.38, −0.25]; p < 0.001). Participants who ceased smoking after diagnosis exhibited more favorable cancer outcomes (pooled log HR: −0.33; 95% CI: [−0.42, −0.24]; p < 0.001), with smoking cessation notably reducing cancer-specific mortality among lung cancer survivors (pooled log HR: −0.34; 95% CI: [−0.48, −0.20]; p < 0.001). Additionally, reducing alcohol intake post-diagnosis significantly improved cancer outcomes (pooled log HR: −0.26; 95% CI: [−0.33, −0.19]; p < 0.001). Alcohol moderation in gastrointestinal tract cancer survivors specifically decreased both cancer-specific mortality and recurrence (pooled log HR: −0.22; 95% CI: [−0.29, −0.15]; p < 0.001). Conclusions: Lifestyle modifications after cancer diagnosis significantly improve cancer-specific outcomes. Specific dietary patterns, increased physical activity, smoking cessation, and reduced alcohol intake are all associated with lower cancer-specific mortality. Integrating these lifestyle changes into oncology care may enhance patient survival and quality of life.

1 July 2011 in Indian Journal of Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
SAShiekh Aejaz Aziz
Shiekh Aejaz Aziz
BLBashir Ahmad Laway
Bashir Ahmad Laway
IRImran Rangraze
Imran Rangraze
MLMohd Iqbal Lone
Mohd Iqbal Lone
SASyed Nisar Ahmad
Syed Nisar Ahmad
Primary adrenal Non-Hodgkin's lymphoma is rare. The symptoms of the disease and response to treatment are variable depending on the type of lymphoma, tumor size, and presence of adrenal insufficiency. We report two cases of primary adrenal lymphoma who had varied presentations. One presenting with abdominal pain and weight loss was documented to have unilateral disease without any adrenal insufficiency and showed a good response to combination chemotherapy, while the second one had bilateral adrenal involvement with adrenal insufficiency and died after second chemotherapy. Functional adrenal involvement in lymphoma depends on the extent of involvement; patients with bilateral involvement almost always have adrenal insufficiency.

1 January 2025 in Advances in Pharmacological and Pharmaceutical Sciences
Verified
Journal Article
Open access
MHMd Sadique Hussain
Md Sadique Hussain
PMPrince Ahad Mir
Prince Ahad Mir
NKNishant Kumar
Nishant Kumar
RMRoohi Mohi-ud-din
Roohi Mohi-ud-din
AWAdil Farooq Wali
Adil Farooq Wali
Mohamed El-TananiMohamed El-Tanani
Mohamed El-Tanani
Drug repurposing, the process of identifying new therapeutic uses for existing drugs, has emerged as a cost‐effective and time‐saving alternative to traditional drug development. This strategy leverages the known pharmacological and safety profiles of approved or investigational drugs to accelerate their clinical application for other diseases. In recent years, repurposed drugs have played a crucial role in addressing treatment gaps in complex and multifactorial diseases such as cancer, neurodegenerative disorders and infectious diseases. This review highlights prominent examples where repurposed drugs have successfully transitioned from laboratory findings to clinical application. We discuss key molecular mechanisms, including polypharmacology and target pathway modulation that enable repositioning. Emphasis is also placed on advances in computational approaches, network pharmacology and data‐driven tools that enhance repurposing efforts. Additionally, we outline the challenges related to regulatory hurdles, intellectual property and clinical validation. By analysing these success stories, we aim to provide a strategic framework to guide future drug repurposing initiatives.